DNA REPAIR ON THE FANCONI ANAEMIA PATHWAY
Associate Professor Wayne Crismani
Laboratory Head, DNA Repair & Recombination
St Vincent’s Institute of Medical Research,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Associate Professor Wayne Crismani is an internationally recognised expert in DNA repair, with a particular focus on Fanconi anaemia (FA)—a cancer-predisposition and bone marrow failure syndrome marked by extreme sensitivity to DNA damage. Based at St Vincent’s Institute in Melbourne, he leads a research program dedicated to understanding the genetic, cellular, and reproductive consequences of FA. He is currently supported by a Victorian Cancer Agency Mid-Career Fellowship and funding from the National Health and Medical Research Council.
His career spans academia and industry across Australia, Europe, and the United States. He has contributed to several advances in FA genetics, including the identification of new functions of FA genes, particularly in reproduction, development of isogenic cell models, and use of high-throughput functional and screening assays. He has also demonstrated that FA is under-diagnosed in Australia, which has major consequences for these individuals and for the public healthcare system. His research has been published in top-tier journals and underpins several patents, including technologies that have been successfully licensed.
Associate Professor Crismani also leads multidisciplinary studies investigating fertility and cancer risk in individuals with FA. These include the first systematic study of biological parenthood and assisted reproductive technologies in adults with FA, and efforts to identify early biomarkers of oral cancer in this high-risk group. His work is conducted in close collaboration with scientists, clinicians, fertility specialists, and patient advocates. He co-founded Fanconi Anaemia Support Australasia with a group of families in 2019 and continues to organise scientific and social events for the FA community.
He works with international FA registries, research consortia, and the Fanconi Cancer Foundation to ensure research findings inform real-world care. His program bridges molecular biology, reproductive health, and translational science, with the goal of improving health outcomes for people with FA and genetic conditions.
Source: Supplied
-
Risk factors and prevention of respiratory infections and infectious diseases in children
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
